NCT01511432View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions
Chronic Hepatitis C
Interventions
DRUG

telaprevir formulation A

A single 1125-mg dose administered orally

DRUG

telaprevir Formulation B

A single 1125-mg dose administered orally

DRUG

telaprevir Formulation C

A single 1125-mg dose administered orally

DRUG

telaprevir Formulation D

A single 1125-mg dose administered orally

Trial Locations (2)

53704

Wisconsin, Madison

75247

Texas, Dallas

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01511432 - A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects | Biotech Hunter | Biotech Hunter